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http://dx.doi.org/10.1016/j.pedneo.2Pelizaeus-Merzbacher disease (PMD) is an X-linked recessive disorder affecting myelination of
the central nervous system, and is caused by mutations of the proteolipid protein 1 (PLP1)
gene. Clinical manifestations of PMD are variable and major features include progressive nys-
tagmus, spasticity, tremor, ataxia, and psychomotor delay. We describe a classical PMD patient
who had been misdiagnosed as cerebral palsy. He had nystagmus and psychomotor delay since
infancy and tremor with ataxia developing gradually. Brain MRI revealed demyelination over
white matter of the cerebral hemispheres and posterior limbs of the internal capsules. Positive
family history led to subsequent mutation analysis, which identified a novel mutation
(c.88G>C) in PLP1 in the proband, as well as his affected brother and maternal uncle, and
asymptomatic maternal grandmother, mother and two sisters. Therefore, PMD should be con-
sidered in a cerebral palsy-like patient with or without positive family history. Mutation ana-
lysis is crucial for early diagnosis and further genetic counseling.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.First Road, Kaohsiung 807, Taiwan.
org.tw (W.-C. Liang).
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PMD, a CP-like hereditary disease 1511. Introduction mild to moderate cognitive difficulties. No nystagmus isPelizaeus-Merzbacher disease (PMD) is a rare X-linked
recessive demyelinating leukodystrophy in the central
nervous system (CNS).1 Major clinical features of PMD
include progressive nystagmus, spasticity, tremor, hypo-
tonia, ataxia, and psychomotor delay in infancy or early
childhood. PMD is caused by mutations of the proteolipid
protein 1 (PLP1) gene on X chromosome (Xq21-22).1 The
PLP1 encodes the myelin proteolipid protein (PLP) and
DM20, an alternatively splicing product of PLP. 2 PLP is the
most abundant membrane protein of CNS myelin2 and may
be a mediator for membrane signaling.3 More than 100
mutations of PLP1 have been found in PMD, including
duplications, point mutations, insertions and deletions.1
Duplication is the most common type among these muta-
tions.4,5 Various mutations of PLP1 lead to abnormal mye-
lination, death of oligodendroglia in the CNS, secondary
axonal loss, and have been implicated in a wide spectrum
of neurologic diseases.2,6
PMD is clinically classified to connatal, classic, transi-
tional, X-linked spastic paraplegia Type 2 (SPG2), and PLP1
null syndrome.1 The patients with connatal PMD show the
most severe phenotype, including nystagmus, hypotonia,
developing spasticity, respiratory distress, and seizures at
birth or during the first week of life. Most connatal PMD
patients die of aspiration problems before age 10 years.
Classic PMD is the most common type of PMD. These
patients develop the symptoms without respiratory
involvement within the first year of life and can survive
until the sixth decade of life. Transitional PMD patients
have overlapping features between the connatal and classic
forms. SPG2 is a milder form of PMD, presenting with the
clinical features in the first 5 years of life. Only SPG2
patients can reproduce, in contrast to all other forms of
PMD. PLP1 null syndrome is caused by null mutation and
presents in the first 5 years of life. PLP1 null syndrome
patients develop mild spastic quadriparesis, ataxia, andFigure 1 Brain MRI of the index case showed high signal intensity
posterior limbs of the internal capsule. Axial MRI (TE: 101.088 ms,observed in PLP1 null syndrome patients. Diagnosis of PMD
depends on clinical features, brain magnetic resonance
imaging (MRI), and genetic testing of PLP1. T2-weighted
and FLAIR brain MRI shows diffuse or patchy high signal
intensity in the white matter of the cerebrum, cerebellum,
and brainstem, suggesting demyelination in these affected
areas and allowing an accurate assessment.7,8
In this report, we describe a classical PMD patient who
had been misdiagnosed as cerebral palsy. Mutation analysis
revealed a novel mutation (c.88G>C) in Exon 1 of PLP1.
Further screening of his three-generation family identified
asymptomatic female carriers, which thus makes genetic
counseling possible.
2. Case Report
The 29-year-old male patient had been diagnosed as cere-
bral palsy. He was brought to our outpatient department for
counseling due to a positive family history of other family
members. He was wheelchair-bound but could transfer
himself with arms. He was aware of the surroundings and
able to communicate with others although with dysarthria.
Neurological examination revealed increased muscle tones
and deep tendon reflexes, especially in lower extremities.
Horizontal nystagmus and head tremor were also observed.
Scoliosis and joint contractures in ankles were present.
Tracing the patient’s history, prenatal examinations were
uneventful. He was born full term via smoothly spontaneous
delivery. At age 3e4 months, poor head control and roving
eye movements were observed. Progressive lower limb
spasticity also developed gradually. He could not sit inde-
pendently until age 5 years. He also had speech delay with
dysarthria. Neither respiratory insufficiency nor seizure was
noted during his growing up. His mental development was
mildly retarded but he was socially interactive. As for the
family history, he was the second child of non-
consanguineous parents. His two sisters were healthy. Hisin the white matter of (A) the cerebral hemispheres and (B) the
TR: 400 ms).
Figure 2 Mutation analysis of the three-generation pedigree of the family. (A) Sequence analysis of Exon 1 of the PLP1 shows a
c.88G>C missense mutation. (B) Pedigree of the three-generation pedigree indicates affected, carrier and unaffected individuals.
-Z affected male; ◉ Z carrier female; bZ proband; *Z DNA obtained.
152 Y.-C. Chen et alyounger brother had similar but more severe symptoms.
General muscle weakness was observed since birth. Then
nystagmus, head tremor, dysarthria, seizures, spasticity in
all extremities, and severe cognitive impairment gradually
developed. He needed a wheelchair and had no self-care
ability. His maternal uncle also had similar clinical features
as the index patient. He developed nystagmus, lower
extremity weakness, mild dysarthria, and slight mental
retardation. He had used a wheelchair since age 9e10 and
now lived independently. All were diagnosed as cerebral
palsy. No associated neurophysiological tests had been
performed.
Based on the findings above, we arranged for further
brain images. T2-weighted brain MRI of the patient showed
high signal intensity over the white matter of the cerebral
hemispheres and posterior limbs of the internal capsules
(Figure 1), indicating diffuse demyelination within these
areas, which led to the diagnosis of PMD. Chromosomal and
mutation analyses were subsequently done, which revealed
male karyotype, 46, XY and a novel missense mutation
c.88G>C in Exon 1 of the PLP1 (p.Ala30Pro). We therefore
screened the three-generation family of the proband for
this mutation. c.88G>C in PLP1 was identified in his
symptomatic brother and uncle, as well as asymptomatic
members including maternal grandmother, mother and two
sisters, but not in his father or asymptomatic uncle
(Figure 2).
Accordingly, the patient was finally diagnosed as classi-
cal PMD with a novel missense mutation (c.88G>C) in Exon
1 of the PLP1.
3. Discussion
As in the PMD patient in our report, this disease is often
misdiagnosed as cerebral palsy because of the similar
phenotypes in infancy or early childhood. To make a dif-
ferential diagnosis between PMD and cerebral palsy is
important for genetic counseling and outcome prediction.
Cerebral palsy is characterized as a disorder of motor
impairment with nonprogressive course due to an insult in
the immature brain. As a result, the key characteristics to
distinguish PMD from cerebral palsy include progressive
pattern, a positive male-to-male family history and some
uncommon features such as tremor and nystagmus. BrainMRI also plays an important role differentiating PMD and
cerebral palsy. Brain MRI of cerebral palsy patients often
shows white matter damage in periventricular areas and
the basal ganglia.9 In contrast, brain MRI of PMD may reveal
leukodystrophy in the entire central white matter of the
cerebrum, cerebellum, and brainstem. In addition to image
study, mutation analysis of PLP1 is also essential for early
diagnosis of PMD.
PLP is a 276-residue integral membrane protein with four
a-helix transmembrane domains. Point mutations of the
transmembrane domains of PLP have been demonstrated to
cause aberrant assembly of PLP and lead to PLP being
retained in the endoplasmic reticulum.10,11 Previous studies
have also shown that PLP transmembrane domain muta-
tions could trigger the unfolded protein response, oligo-
dendrocyte apoptosis, and demyelination of the CNS.12,13
Here, we report a novel missense mutation of G to C
change at nucleotide 88 in the PLP1. The mutation results
in an alanine to proline substitution in the first trans-
membrane domain of the PLP. Therefore, this PLP mutant is
assumed to influence the stability of transmembrane
structure, resulting in protein misfolding and accumulation
in the endoplasmic reticulum, and leading to clinical dis-
orders of PMD.
In conclusion, if a cerebral palsy-like patient presents
with a progressive course and diffuse white matter
involvement in brain MRI, PMD should be considered first
whether this is a sporadic condition or there is a positive
family history. Genetic analysis may be of great help for
early diagnosis.
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